These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 18979581)

  • 1. Effects of infliximab and parenteral nutrition on albumin and fibrinogen synthesis rates in pediatric Crohn disease.
    Steiner SJ; Pfefferkorn MD; Fitzgerald JF; Denne SC
    J Pediatr Gastroenterol Nutr; 2008 Nov; 47(5):579-84. PubMed ID: 18979581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein and energy metabolism response to the initial dose of infliximab in children with Crohn's disease.
    Steiner SJ; Pfefferkorn MD; Fitzgerald JF; Denne SC
    Inflamm Bowel Dis; 2007 Jun; 13(6):737-44. PubMed ID: 17243138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Analysis of infliximab treated pediatric patients with Crohn disease in Hungary].
    Veres G; Szabó D; Várkonyi A; Tari B; Polgár M; B Kovács J; Horváth A; Tomsits E; Tokodi I; Bodánszky H; Dezsofi A; Szakos E; Vass N; Ruszinkó V; Kovács M; Müller KE; Arató A
    Orv Hetil; 2010 Jan; 151(5):179-83. PubMed ID: 20083466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carbohydrate and lipid metabolism following infliximab therapy in pediatric Crohn's disease.
    Steiner SJ; Pfefferkorn MD; Fitzgerald JF; Denne SC
    Pediatr Res; 2008 Dec; 64(6):673-6. PubMed ID: 18679167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin infusion normalizes fasting and post-prandial albumin and fibrinogen synthesis in Type 1 diabetes mellitus.
    Bruttomesso D; Iori E; Kiwanuka E; Zanetti M; Pianta A; Vettore M; Tiengo A; Tessari P
    Diabet Med; 2001 Nov; 18(11):915-20. PubMed ID: 11703437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease.
    Lamireau T; Cézard JP; Dabadie A; Goulet O; Lachaux A; Turck D; Maurage C; Morali A; Sokal E; Belli D; Stoller J; Cadranel S; Ginies JL; Viola S; Huet F; Languepin J; Lenaerts C; Bury F; Sarles J;
    Inflamm Bowel Dis; 2004 Nov; 10(6):745-50. PubMed ID: 15626892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.
    Maser EA; Villela R; Silverberg MS; Greenberg GR
    Clin Gastroenterol Hepatol; 2006 Oct; 4(10):1248-54. PubMed ID: 16931170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience.
    Cohen RD
    Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S17-22. PubMed ID: 11380038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab improves inflammation and anthropometric measures in pediatric Crohn's disease.
    Sinitsky DM; Lemberg DA; Leach ST; Bohane TD; Jackson R; Day AS
    J Gastroenterol Hepatol; 2010 Apr; 25(4):810-6. PubMed ID: 20492339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of concomitant elemental diet therapy in scheduled infliximab therapy in patients with Crohn's disease to prevent loss of response.
    Kamata N; Oshitani N; Watanabe K; Watanabe K; Hosomi S; Noguchi A; Yukawa T; Yamagami H; Shiba M; Tanigawa T; Watanabe T; Tominaga K; Fujiwara Y; Arakawa T
    Dig Dis Sci; 2015 May; 60(5):1382-8. PubMed ID: 25532505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
    Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab therapy in 30 patients with refractory pediatric crohn disease with and without fistulas in The Netherlands.
    de Ridder L; Escher JC; Bouquet J; Schweizer JJ; Rings EH; Tolboom JJ; Houwen RH; Norbruis OF; Derkx BH; Taminiau JA
    J Pediatr Gastroenterol Nutr; 2004 Jul; 39(1):46-52. PubMed ID: 15187780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab delays but does not avoid the need for surgery in treatment-resistant pediatric Crohn' disease.
    Afzal NA; Ozzard A; Keady S; Thomson M; Murch S; Heuschkel R
    Dig Dis Sci; 2007 Dec; 52(12):3329-33. PubMed ID: 17805970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous measurement of albumin and fibrinogen synthetic rates in normal fasted subjects.
    McMillan DC; Slater C; Preston T; Falconer JS; Fearon KC
    Nutrition; 1996 Sep; 12(9):602-7. PubMed ID: 8878169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Albumin synthesis rates measured with [2H5ring]phenylalanine are not responsive to short-term intravenous nutrients in healthy humans.
    Ballmer PE; McNurlan MA; Essen P; Anderson SE; Garlick PJ
    J Nutr; 1995 Mar; 125(3):512-9. PubMed ID: 7876926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy of adalimumab in paediatric Crohn's disease patients naïve to other anti-TNF therapies.
    Martín-de-Carpi J; Pociello N; Varea V
    J Crohns Colitis; 2010 Nov; 4(5):594-8. PubMed ID: 21122566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of infliximab in the treatment of peripheral ulcerative keratitis in Crohn disease.
    Pham M; Chow CC; Badawi D; Tu EY
    Am J Ophthalmol; 2011 Aug; 152(2):183-188.e2. PubMed ID: 21652024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism.
    Louis E; Vermeire S; Rutgeerts P; De Vos M; Van Gossum A; Pescatore P; Fiasse R; Pelckmans P; Reynaert H; D'Haens G; Malaise M; Belaiche J
    Scand J Gastroenterol; 2002 Jul; 37(7):818-24. PubMed ID: 12190096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.
    Kugathasan S; Werlin SL; Martinez A; Rivera MT; Heikenen JB; Binion DG
    Am J Gastroenterol; 2000 Nov; 95(11):3189-94. PubMed ID: 11095340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (remicade) in severe pediatric crohn disease.
    Cezard JP; Nouaili N; Talbotec C; Hugot JP; Gobert JG; Schmitz J; Mougenot JF; Alberti C; Goulet O
    J Pediatr Gastroenterol Nutr; 2003 May; 36(5):632-6. PubMed ID: 12717087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.